Huma Therapeutics GmbH

Founded in 2011 and based in London, UK, uma Therapeutics GmbH, operates as a provider of mobile health solution that delivers patient information and clinical applications to doctors. The company was founded by its CEO Dan Vahdat, and Rich Khatib. As of 2023, the company employs more than 500 employees. In May 2022, the firm raised GBP 25.

82 million in venture funding led by investor AstraZeneca. The round of financing values Huma Therapeutics Limited at GBP 222. 92 million post-money. Huma provides healthcare applications and solutions that combine health data from existing hospital databases as well as patient wearables and other mobile devices and securely transmits it for use by doctors via iPads and other mobile devices.

By using the application, Healthcare professionals can securely access lab results, images, clinical notes, and primary care data, and hospitals can convert their patient data into a single platform so that it can be accessed by doctors in real-time when they are consulting a patient. The firm’s offerings also allow patients to send photos, take video conferences, share primary records, and transmit their real-time vital signs with biomarker devices such as apple watch with their doctors. The company offers various platforms such as hospital at home, virtual wards, remote patient monitoring USA, decentralized clinical trials, and companion apps for pharma and medtech. The company plan to use the May 2022 funding to accelerate its expansion in the US.